Eplerenone for the treatment of cardiovascular disorders.
The clinical utility and ultimately guideline recommendations for aldosterone receptor-blocking agents in cardiovascular disorders is clearly mentioned by a number of major clinical outcome trials. This article reviews the pharmacology, clinical efficacy and safety of the two currently available receptor blocking agents: spironolactone and eplerenone. The potential utility of eplerenone and other mineralocorticoid receptor agents beyond current clinical indications will also be examined.
Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics Monash University, L6, The Alfred Centre, 99 Commercial Road, Melbourne, VIC 3004, Australia.
Masataka
M
Watanabe
Henry
H
Krum
D000450:Aldosterone / Q000378:metabolism; D000818:Animals; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D000077545:Eplerenone; D006801:Humans; D006854:Hydrocortisone / Q000037:antagonists & inhibitors / Q000378:metabolism; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018161:Receptors, Mineralocorticoid / Q000378:metabolism; D013148:Spironolactone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D002317:Cardiovascular Agents; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone; D006854:Hydrocortisone